EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential

• Giovanni Sette,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Valentina Salvati,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Lorenzo Memeo,

  Affiliation Mediterranean Institute of Oncology, Catania, Italy

  ⨯
• Katia Fecchi,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Cristina Colarossi,

  Affiliation Mediterranean Institute of Oncology, Catania, Italy

  ⨯
• Paola Di Matteo,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Michele Signore,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Mauro Biffoni,

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯
• Vito D’Andrea,

  Affiliation Department of Surgical Sciences, La Sapienza University of Rome, Italy

  ⨯
• Enrico De Antoni,

  Affiliation Department of Surgical Sciences, La Sapienza University of Rome, Italy

  ⨯
• Vincenzo Canzonieri,

  Affiliation Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy

  ⨯
• Ruggero De Maria,

  Affiliation Regina Elena National Cancer Institute, Rome, Italy

  ⨯
• Adriana Eramo

  * E-mail: adriana.eramo@iss.it

  Affiliation Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

  ⨯